“Can We Declare Victory and Move On?” The Case Against Funding Burden-of-Disease Studies

Steven Kymes ()

PharmacoEconomics, 2014, vol. 32, issue 12, 1153-1155

Abstract: Resources devoted to the development of burden-of-disease studies detract from much needed cost-effectiveness and cost-benefit studies. Practitioners need to help funders of burden-of-disease projects recognize the potential of all tools of decision analysis and economic evaluation in improving the efficiency and equity for the health care system. Copyright Springer International Publishing Switzerland 2014

Date: 2014
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.1007/s40273-014-0200-8 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:32:y:2014:i:12:p:1153-1155

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-014-0200-8

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().